1. Lajara R. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin Pharmacother 2012; 13: 2663-71. [DOI:10.1517/14656566.2012.741591]

2. Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther 2011; 28: 447-59. [DOI:10.1007/s12325-011-0028-y]

3. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 2003; 29: S628-35. [DOI:10.1016/S1262-3636(03)72785-2]

4. Haak T. Combination of linagliptin and metformin for the treatment of patients with Type 2 diabetes. Clin Med Insights Endocrinol Diabetes 2015; 8: 1-6. [DOI:10.4137/CMED.S10360]

5. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 2006; 29: 2632-37. [DOI:10.2337/dc06-0703]

6. Lv Q, Shen J, Miao L, Ye B, Schepers C, Plat A, et al. Early combination therapy with linagliptin and metformin in people with Type 2 diabetes improves glycemic control to HbA1c ≤ 6.5% without increasing hypoglycemia: pooled analysis of two randomized clinical trials. Diabetes Ther 2020; 11: 1317-30. [DOI:10.1007/s13300-020-00819-9]

7. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind non-inferiority trial. Lancet 2012; 380: 475-83. [DOI:10.1016/S0140-6736(12)60691-6]

8. Scheen AJ. Efficacy and safety of Jentadueto® (linagliptin plus metformin). Expert Opin Drug Saf 2013; 12: 275-89. [DOI:10.1517/14740338.2013.771631]

9. Sortino MA, Sinagra T, Canonico PL. Linagliptin: A thorough Characterization beyond Its Clinical Efficacy. Front Endocrinol (Lausanne) 2013; 4: 16. [DOI:10.3389/fendo.2013.00016]

10. Siavash M, Tabbakhian M, Sabzghabaee AM, Razavi N. Severity of gastrointestinal Side Effects of metformin Tablet Compared to Pharm Pract 2017; 6: 73-76. [DOI:10.4103/jrpp.JRPP_17_2]

11. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in Type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79. [DOI:10.2337/dc12-0413]

12. Christian Ebere E, Obinna Isiuku B, Andrew Wirnkor V. Applications of column, paper, thin layer and ion exchange chromatography in purifying samples: mini review. SF J. Pharm Anal Chem. 2019; 2: 1-6.

13. Mlik G, Beyazaslan F, Bilakaya B, Degim IT. Simultaneous Determination of Linagliptin and Metformin by Reverse Phase-High Performance Liquid Chromatography Method: An Application in Quantitative Analysis of Pharmaceutical Dosage Forms. Austin Chromatogr 2023; 8: 1055.

14. Akay C, Deǧim IT, Sayal A, Aydin A, Özkan Y, Gül H. Rapid and simultaneous determination of acetylsalicylic acid, paracetamol,and their degradation and toxic impurity products by HPLC in pharmaceutical dosage forms. Turk J Med Sci 2008; 38: 167-73.

15. Değim T, Akay C, Büyükafşar K, Cevheroğlu S. Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC. J Pharm Biomed Anal 2001; 26: 15-21. [DOI:10.1016/S0731-7085(01)00392-2]

16. Kowalska M, Woźniak M, Kijek M, Mitrosz P, Szakiel J, Turek P. Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product. Sci Rep 2022; 12: 1. [DOI:10.1038/s41598-021-99269-x]

17. Guideline IHT. Impurities in new drug substances, Q3A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2008. Available from: https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf

18. Guideline IHT. Impurities in new drug products, Q3B (R2). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2006. Available from: https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf

19. Liu DQ, Wu L, Sun M, MacGregor PA. On-line H/D exchange LC- MS strategy for structural elucidation of pharmaceutical impurities. J Pharm Biomed Anal 2007; 44: 320-9. [DOI:10.1016/j.jpba.2007.01.019]

20. Uslu B, Özkan SA. Determination of Lamivudine and Zidovudine in binary mixtures using first derivative spectrophotometric, first derivative of the ratio-spectra and high-performance liquid chromatography-UV methods. Anal Chim Acta 2002; 466: 175- 85. [DOI:10.1016/S0003-2670(02)00545-7]

21. Ozkan SA, Uslu B. Rapid HPLC assay for lamivudine in pharmaceuticals and human serum. J Liq Chromatogr Relat Technol 2002; 25: 1447-56. [DOI:10.1081/JLC-120004759]

22. Pham-Huy C, Stathoulopoulou F, Sandouk P, Scherrmann JM, Palombo S, Girre C. Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution. J Chromatogr B Biomed Sci Appl 1999; 732: 47-53. [DOI:10.1016/S0378-4347(99)00261-3]

23. Guideline IHT. Validation of analytical procedures, Q2. In: International conference of harmonization. Geneva, Switzerland. 2022; R1. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf

24. Hacıoğlu A, Çıtlak A, Karakuş S. Development and Validation of HPLC Method for Determination of Nateglinide in Drug Substances. J Res Pharm 2015;19:103-108. [DOI:10.12991/mpj.2015199640]